Edwards Lifesciences Corporation $EW Shares Purchased by Cibc World Market Inc.

Cibc World Market Inc. boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 37.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,601 shares of the medical research company’s stock after purchasing an additional 9,120 shares during the period. Cibc World Market Inc.’s holdings in Edwards Lifesciences were worth $2,864,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Washington Trust Advisors Inc. lifted its position in Edwards Lifesciences by 15.6% in the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after purchasing an additional 17,625 shares during the period. Azzad Asset Management Inc. ADV lifted its position in Edwards Lifesciences by 330.5% in the third quarter. Azzad Asset Management Inc. ADV now owns 21,227 shares of the medical research company’s stock valued at $1,651,000 after purchasing an additional 16,296 shares during the period. Elo Mutual Pension Insurance Co lifted its position in Edwards Lifesciences by 39.9% in the third quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock valued at $6,974,000 after purchasing an additional 25,562 shares during the period. Oppenheimer Asset Management Inc. lifted its position in Edwards Lifesciences by 57.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 37,880 shares of the medical research company’s stock valued at $2,946,000 after purchasing an additional 13,820 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Edwards Lifesciences by 27.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after purchasing an additional 23,514 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.1%

Shares of Edwards Lifesciences stock opened at $85.92 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $89.48. The company has a market capitalization of $49.47 billion, a P/E ratio of 45.70, a P/E/G ratio of 2.16 and a beta of 0.87. The business has a 50 day moving average price of $82.29 and a 200 day moving average price of $83.07.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the firm posted $0.64 EPS. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on EW. BTIG Research raised their price objective on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, April 24th. TD Cowen reissued a “buy” rating and set a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Barclays reissued an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Finally, Mizuho set a $95.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at $3,371,239.08. The trade was a 24.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 95,057 shares of company stock worth $7,874,217 in the last ninety days. Insiders own 0.31% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.